| INTRODUCTION
Basal cell carcinoma is the most common skin cancer developing with various clinical and histologic features mostly in parts of the body exposed to UV-light. Especially, the head and neck area is at risk. Some tumors develop in other parts of the body and may be part of a rare genetic syndrome. 1 Therapy for locally advanced tumors includes surgical excisions with clear margins, laser or radiotherapy, and in advanced stages hedgehog pathway inhibitors, chemotherapy, and PDL-1 immunotherapy in study protocols. 2 Metastatic disease is unexpected and occurs according to the literature in only 0.025%-0.55%. 
| CASE REPORT
A 50-year-old otherwise healthy, nonimmunosuppressed male presented with several basal cell carcinomas and a rodent ulcer, on his right shoulder, which was resected with clear margins followed by radiotherapy to the primary tumor site ( Figure 1) . Because of the size of the primary tumor, 60 Gy was administered.
Initial ultrasound examination of the right axilla showed a lymph node measuring 1.8 × 1 × 1 cm, which was classified as unspecific lymph node enlargement. The patient presented 3 years after initial treatment with sudden extensive lymph edema of the right upper extremity. On clinical examination, there was no lymph node enlargement palpable in the right axilla; however, ultrasound revealed only one suspicious lymph node (Figure 2) .
Preoperative PET-CT demonstrated two lymph nodes in the right axillary region and no evidence of further metastasis ( Figure 3 ). The patient was admitted for lymphadenectomy. Histologic examination revealed only one metastatic lymph node with basaloid differentiation and perinodular infiltration and one lymph node with unspecific inflammation. 
| CONCLUSION
There are still ongoing discussions how to treat metastasized basal cell carcinoma, thus making individual strategies necessary. Individualized therapy depends on tumor load and localization. Today's options include hedgehog inhibitors, surgery, and radiotherapy. Recent studies include PD1 inhibitor therapy and tumor vaccination (Jäger, unpublished data/personal communication). In this case, lymphedema, as an early warning sign, led to timely intervention and further recurrence free survival till date.
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